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Authors’ reply Thank you for your valuable com‑ 
ment. Our review of December 2017 focused on 
recent observations regarding altered fibrin clot 
phenotype associated with thromboembolic 
events, including myocardial infarction, stroke, 
and venous thromboembolism.1 In patients with 
systemic inflammatory diseases, such as rheu‑ 
matoid arthritis (RA) as well as chronic obstruc‑ 
tive pulmonary disease (COPD), a prothrombot‑ 
ic state involving reduced clot permeability and 
prolonged lysis time has been shown to be associ‑ 
ated with disease activity.2,3 One might speculate 
that such prothrombotic fibrin clot phenotype 
contributes to the elevated risk of thrombosis in 
patients with active RA. However, to what extent 
altered fibrin clot structure and function may in‑ 
crease the risk of arterial and venous thrombo‑ 
sis in RA remains to be established in large pro‑ 
spective studies. Such impact of fibrin variables 
has been shown for recurrent venous thrombo‑ 
embolism during follow ‑up.4 
Although many antiplatelet, anticoagulant, or 
cholesterol ‑lowering agents have been shown to 
favorably modulate fibrin properties,1,2 the in‑ 
fluence of steroids or specific antibodies (ie, in‑ 
fliximab) on fibrin clot phenotype, especially in 
patients with systemic inflammatory diseases, 
is unknown. Growing evidence indicates that 
the treatment with anti–tumor necrosis factor α 
antibodies can suppress blood coagulation.3 Sim‑ 
ilarly, patients with RA treated with tocilizum‑ 
ab, an interleukin ‑6 receptor inhibitor, showed 
a reduction in the levels of inflammatory mark‑ 
ers, followed by a decrease in prothrombin frag‑ 
ment F1+2 and D ‑dimer levels.5 This suggests that 
immunothrombosis is involved in RA ‑induced 
thrombosis, but the role of fibrin properties is 
unclear in this context. Therefore, we absolute‑ 
ly agree that further studies of patients with RA, 
with long ‑term follow ‑up, and with thromboem‑ 
bolic events as primary endpoints are warranted.
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